Metastatic Prostate Cancer Clinical Trial
Official title:
Evaluation of the Technical Feasibility of Testing Circulating Tumour DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.
Evaluation of technical feasibility for Homologous Recombination (HR) genes variants research on circulating tumor DNA (ctDNA) from plasma and urine of patients with a metastatic prostate cancer.
The benefit of PARPi has been well established for ovarian (SOLO-1 study) and prostate cancer (PROFOUND study) with defects in the Homologous Recombination Repair (HRR) system due to BRCA1 or BRCA2 variants. Somatic variants in HRR genes are currently researched by Next Generation Sequencing (NGS). However, in metastatic prostate cancer, using formalin-fixed and paraffin-embedded (FFPE) samples, failure rate is around 30 % according to our retrospective datas, in agreement with the data of the PROFOUND study, highlighting a real pre-analytical matter when FFPE samples are used for NGS testing. Research of such alterations on circulating tumor DNA (ctDNA) extracted from plasma or urine could be a promising alternative test. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Recruiting |
NCT04533958 -
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT06009549 -
A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
|
||
| Withdrawn |
NCT05771896 -
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
|
Phase 3 | |
| Completed |
NCT01981122 -
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01233557 -
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
|
N/A | |
| Completed |
NCT01012141 -
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT04067713 -
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
|
||
| Active, not recruiting |
NCT04332744 -
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
|
Phase 2 | |
| Completed |
NCT04545697 -
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer
|
N/A | |
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02278055 -
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT04193657 -
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
|
||
| Completed |
NCT02260817 -
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT00216060 -
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
|
Phase 3 | |
| Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
| Recruiting |
NCT04925648 -
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
|
Phase 2 | |
| Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 |